NRSN

$0.82

Post-MarketAs of Mar 17, 8:00 PM UTC

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.82
Potential Upside
5%
Whystock Fair Value$0.86
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead pr...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.69

Recent News

MT Newswires
Sep 10, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
May 12, 2025

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Last Wednesday, NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) said it scaled up its production of PrimeC to a commercial scale. PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. NeuroSense said it bolstered its supply chain by implementing comprehensive Chemistry, Manufacturing, and Controls (CMC) enhan

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.